{"favorite_id": 10382, "calc_type": "", "dosing": false, "full_title_en": "Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism", "short_title_en": "IRAE for Endocrine Toxicities - Hypothyroidism", "medium_description_en": "Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy.", "short_description_en": "Hypothyroidism severity (ICPi therapy).", "before_use": "", "instructions_en": "<p>Use in adult patients with symptoms of hypothyroidism and/or abnormalities of TSH or free thyroxine level that developed while on treatment with immune checkpoint inhibitors.</p>", "purpose_en": ["Diagnosis", "Prognosis"], "disease_en": ["Hypothyroidism"], "specialty_en": ["Allergy and Immunology", "Endocrinology", "Hospitalist Medicine", "Internal Medicine"], "chief_complaint_en": ["Fatigue", "Weight Loss/Gain"], "system_en": ["Endocrine and Metabolic"], "search_abbreviation_en": ["Immune Related Adverse Events, irae, hypothyroidism, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"], "slug": "immune-related-adverse-events-endocrine-toxicities-hypothyroidism", "seo": {"meta_description_en": "The Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy.", "keywords_en": "Immune Related Adverse Events, irae, hypothyroidism, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-8659ee97-7fff-e049-6b3b-63516b4ca327\">Adult patients with symptoms of hypothyroidism and/or abnormalities of TSH or free thyroxine level that developed while on treatment with immune checkpoint inhibitors, including agents against PD-1 (i.e. pembrolizumab, nivolumab), PD-L1 (i.e. atezolizumab, avelumab, durvalumab), or CTLA-4 (i.e. ipilimumab).</p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-0e500928-7fff-4a8d-d769-d0c628466069\"></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Immune checkpoint inhibitor (ICPi) related hypothyroidism should be suspected in patients with TSH, free thyroxine level abnormalities and/or symptoms of hypothyroidism (e.g. extreme tiredness or weakness, weight gain, hair loss, constipation, feeling cold) while on treatment with immune checkpoint inhibitors.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May occur any time during immune checkpoint inhibitor treatment.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">More frequently seen with anti-PD-1 and anti-PD-L1 agents, but also an important adverse event caused by anti-CTLA-4 agents.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Management of ICPi related hypothyroidism is based on grade of hypothyroidism.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-1c0b73c0-7fff-7b00-32e2-03e344a24171\">This tool aids in the decision to discontinue ICPi, further diagnostic work-up, and thyroid hormone supplementation initiation.</p>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-27e9c761-7fff-9c4e-9864-8ead0440f48f\"></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor patients with TSH and free thyroxine every 4 to 6 weeks routinely during ICPi therapy.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Test for TSH and free thyroxine in symptomatic patients.</p>\n</li>\n</ul>", "management_en": "<p dir=\"ltr\">For all patients where an IRAE diagnosis is being considered, it is always recommended to involve the specialist or team prescribing the immune checkpoint therapy.&nbsp;</p>\n<p dir=\"ltr\"><strong>Grade 1:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Continue ICPi with close follow-up and monitoring of TSH, free thyroxine.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 2:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May hold ICPi until symptoms resolve to baseline.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider endocrinology consult.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider thyroid hormone supplementation in symptomatic patients with any degree of TSH elevation or in asymptomatic patients with TSH levels that persist &gt; 10 mIU/L (measured 4 weeks apart).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor TSH every 6 to 8 weeks while titrating hormone replacement to normal TSH.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Free thyroxine can be used in the short term (2 weeks) to ensure adequacy of therapy in those with frank hypothyroidism where the free thyroxine was initially low.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Once adequately treated, monitor thyroid function (at least TSH) every 6 weeks while on active therapy or as needed for symptoms to ensure appropriate replacement.&nbsp;</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 3-4:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Should hold ICPi until symptoms resolve to baseline with appropriate supplementation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider endocrinology consult.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider admission for IV therapy if signs of myxedema (bradycardia, hypothermia).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider thyroid supplementation and offer reassessment as in grade 2.</p>\n</li>\n</ol>\n<p><span id=\"docs-internal-guid-1d5e45a9-7fff-bf1f-ebac-9e7ba32255db\">See <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29442540\" target=\"_blank\" rel=\"noopener\">Brahmer 2018</a> for full ASCO guidelines.</p>", "critical_actions_en": "<p dir=\"ltr\">Distinguishing primary hormonal problems from secondary hormonal problems is necessary.&nbsp;</p>\n<p><span id=\"docs-internal-guid-3c6a7277-7fff-107b-d83e-8550758473b2\"></p>\n<p dir=\"ltr\">Monitoring both TSH and free thyroxine levels helps distinguish primary hypothyroidism from central hypothyroidism which may be due to ICPi hypophysitis.</p>"}, "about": {"formula_en": "<div dir=\"ltr\" align=\"left\">\n<table><colgroup><col /><col /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Hypothyroidism grade</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">TSH &lt;10 mIU/L and asymptomatic</p>\n</td>\n<td>\n<p dir=\"ltr\">G1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Moderate symptoms; able to perform ADLs; TSH persistently &gt;10 mIU/L</p>\n</td>\n<td>\n<p dir=\"ltr\">G2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs</p>\n</td>\n<td>\n<p dir=\"ltr\">G3-4</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">See Next Steps for details on management.</p>", "more_info_en": "", "evidence_based_medicine_en": "<p><span id=\"docs-internal-guid-1a33b805-7fff-4a68-c977-25d5aaadbaa5\">Guidelines for IRAE in Endocrine Toxicities (Hypothyroidism) were developed by a multidisciplinary, multi-organizational panel of experts in medical oncology based on a systematic review of the medical literature.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/29442540 ", "text": "Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768."}], "Other References": [], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Nazli", "img": "", "lastName": "Dizman", "name": "Nazli Dizman, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Julie R. Brahmer", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Julie R. Brahmer, MSc, MD, is the co-director of the upper aerodigestive department at Johns Hopkins Medicine in Baltimore, MD. She is also a professor of oncology at Johns Hopkins Medicine. Dr. Brahmer\u2019s primary research is focused on treatment of lung cancer and mesothelioma.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-julie-brahmer.png", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Brahmer+JR%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Criteria", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "TSH <10 mIU/L and asymptomatic", "value": 1}, {"label": "Moderate symptoms; able to perform ADLs; TSH persistently >10 mIU/L", "value": 2}, {"label": "Severe symptoms, medically significant or life-threatening consequences, unable to perform ADLs", "value": 3}], "name": "grading"}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 10377, "short_title_en": "IRAE for Endocrine Toxicities - Diabetes", "slug": "immune-related-adverse-events-endocrine-toxicities-diabetes-mellitus"}, {"calcId": 10383, "short_title_en": "IRAE for Lung Toxicity - Pneumonitis", "slug": "immune-related-adverse-events-lung-toxicity-pneumonitis"}, {"calcId": 10389, "short_title_en": "IRAE for GI Toxicity - Hepatitis", "slug": "immune-related-adverse-events-gi-toxicity-hepatitis"}]}